Skip to main content
    M

    Mineralys Therapeutics, Inc. Common Stock (MLYS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $14.53
    -0.80 (-5.22%)

    Market Cap: $1.36B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Mineralys Therapeutics, Inc. Common Stock (MLYS) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Mineralys Therapeutics, Inc. Common Stock (MLYS) to earn -$4.59 per share in the fiscal year ending Dec 31, 2026. Of 11 analysts, 9 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 7 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 2.18, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 82% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy981.8%
    Hold218.2%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    11

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$4.59
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$2.60
    EPS consensus, revenue $79.17M
    Next report
    Mar 10, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$4.59-$4.82 to -$4.268N/AN/A7
    Dec 31, 2027-$2.60-$3.78 to -$1.648$79.17M$32.00M to $125.80M9

    Quarterly Estimates

    The EPS consensus falls from -$0.60 for the quarter ending Dec 31, 2026 to -$0.82 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.60-$0.72 to -$0.4711N/AN/A10
    Mar 31, 2027-$0.82-$1.13 to -$0.654$1.40MN/A5

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 0 upward and 10 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202607
    Quarter ending Mar 31, 202703

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$2.24.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$4.59-$4.43-$4.43-$4.43-$2.24N/A
    Fiscal year ending Dec 31, 2027-$2.60-$2.46-$2.50-$2.50-$2.10N/A
    Quarter ending Mar 31, 2027-$0.82-$0.78-$0.78-$0.78-$0.79N/A

    Frequently Asked Questions About MLYS

    What is the MLYS stock forecast?

    Consensus analyst estimates put Mineralys Therapeutics, Inc. Common Stock's EPS at -$4.59 for the fiscal year ending Dec 31, 2026. The consensus rating from 11 analysts is Buy.

    How do analysts rate MLYS stock?

    Of 11 analysts covering Mineralys Therapeutics, Inc. Common Stock, 0 rate it Strong Buy, 9 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from MLYS next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.59, with estimates from -$4.82 to -$4.26 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.60, with estimates from -$3.78 to -$1.64 from 8 analysts.

    What revenue do analysts expect from Mineralys Therapeutics, Inc. Common Stock next year?

    For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $79.17M, with estimates from $32.00M to $125.80M.

    How many analysts cover MLYS?

    11 analysts rate Mineralys Therapeutics, Inc. Common Stock stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.